H5N1 | WHO pandemic phases Image File history File links Colorized_transmission_electron_micrograph_of_Avian_influenza_A_H5N1_viruses. ...
Influenza A virus subtype H5N1, also known as A(H5N1) or H5N1, is a subtype of the Influenza A virus that is capable of causing illness in many species, including humans. ...
The H5N1 genetic structure is the structure of the H5N1 virus. ...
Influenzavirus A is a genus of a family of viruses called Orthomyxoviridae in virus classification. ...
H5N1 flu refers to the transmission and infection of H5N1. ...
The global spread of H5N1 in birds is considered a significant pandemic threat. ...
An influenza pandemic is a large scale epidemic of the influenza virus, such as the 1918 Spanish flu. ...
H5N1 impact is the effect or influence of H5N1 in human society; especially the financial, political, social and personal responses to both actual and predicted deaths in birds, humans, and other animals. ...
An influenza pandemic is a large scale epidemic of the influenza virus, such as the 1918 Spanish flu. ...
- Low risk
- New virus
- Self limiting
- Person to person
- Epidemic exists
- Pandemic exists
| H5N1 clinical trials are clinical trials concerning H5N1 vaccine; which is to say they are investigations concerning H5N1 vaccine in humans intended to discover pharmacological effects and identify any adverse reactions.[1] In medicine, a clinical trial (synonyms: clinical studies, research protocols, medical research) is a research study. ...
A vaccine is an antigenic preparation used to produce active immunity to a disease, in order to prevent or ameliorate the effects of infection by any natural or wild strain of the organism. ...
Influenza A virus subtype H5N1, also known as A(H5N1) or H5N1, is a subtype of the Influenza A virus that is capable of causing illness in many species, including humans. ...
Revaccination - January 2006
Study completion: January 2006
The purpose of this study is to determine whether having received an H5 vaccine in the past primes the immune system to respond rapidly to another dose of H5 vaccine. Subjects who participate in this study will have participated in a previous vaccine study (involving the A/Hong/Kong/97 virus) during the fall of 1998 at the University of Rochester.[2]
A/H5N1 in adult - February 2006 Study start: April 2005; Study completion: February 2006
The purpose of this study is to determine the dose-related safety of flu vaccine in healthy adults. To determine the dose-related effectiveness of flu vaccine in healthy adults approximately 1 month following receipt of 2 doses of vaccine. To provide information for the selection of the best dose levels for further studies.[3]
H5 booster after two doses - June 2006 Study start: October 2005; Study completion: June 2006
The purpose of this study is to determine whether a third dose of vaccines containing A/Vietnam/1203/04 provides more immunity than two doses. Subjects who participate in this study, will have participated in DMID protocol 04-063 involving the A/Vietnam/1203/04. In this study, each subject will be asked to receive a third dose of the H5 vaccine at the same level administered in protocol 04-063.[4]
H5 in the elderly - August 2006 Study start: October 2005; Study completion: August 2006
This study is intended to examine the safety and dose-related immunogenicity of three dosage levels of the Influenza A/H5N1 vaccine, as compared to saline placebo, given intramuscularly to healthy elderly adults approximately 4 weeks apart.[5]
H5 in healthy adults - November 2006 Study start: March 2006; Expected completion: November 2006
This randomized, controlled, double-blinded, dose-ranging, Phase I-II study in 600 healthy adults, 18 to 49 years old, is designed to investigate the safety, reactogenicity, and dose-related immunogenicity of an investigational inactivated influenza A/H5N1 virus vaccine when given alone or combined with aluminum hydroxide. A secondary goal is to guide selection of vaccine dosage levels for expanded Phase II trials based on reactogenicity and immunogenicity profiles. This dose optimization will be applied to both younger and older subject populations in subsequent studies. Subjects who meet the entry criteria for the study will be enrolled at one of up to 5 study sites and will be randomized into 8 groups to receive two doses of influenza A/H5N1 vaccine containing 3.75, 7.5, 15, or 45 mcg of HA with or without aluminum hydroxide adjuvant by IM injection (N= 60 or 120/vaccine dose group).[6]
Bird flu - November 2006 Study start: March 2006; Study completion: November 2006
This study is designed to gather critical information on the safety, tolerability, and the immunogenicity (capability of inducing an immune response) of A/H5N1 virus vaccine in healthy adults. Up to 280 healthy adults, aged 18 to 64, will participate in the study. Each subject will participate for 7 months and will be randomly placed in one of several different study groups receiving a different dose of vaccine, vaccine plus adjuvant, or placebo. All subjects will receive two injections of their assigned study product, about 28 days apart, in their muscle tissue. Subjects will keep a journal of their temperature and any adverse effects between study visits. A small amount of blood will also be drawn before the first injection, 7 days after each injection, and 6 months after the second injection.[7]
Pandemic flu - January 2007 Study start: October 2005; Study completion: January 2007
This study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in healthy adults.[8]
Children - February 2007 Study start: January 2006; Study completion: February 2007
This is a randomized, double-blinded, placebo-controlled, staged, dose-ranging, Phase I/II study to evaluate the safety, reactogenicity, and immunogenicity of 2 doses of an IM inactivated influenza A/H5N1 vaccine in healthy children, aged 2 through 9 years. This study is designed to investigate the safety, tolerability, and dose-related immunogenicity of an investigational inactivated influenza A/H5N1 vaccine. A secondary goal is to identify an optimal dosage level of the vaccine that generates an acceptable immunogenic response, while maintaining an adequate safety profile.[9]
See also
Sources - ^ IFPMA glossary
- ^ clinicaltrials.gov Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine
- ^ clinicaltrials.gov A/H5N1 Adult - Aventis
- ^ clinicaltrials.gov H5 Booster After a Two Dose Schedule
- ^ clinicaltrials.gov H5 Aventis in the Elderly
- ^ clinicaltrials.gov H5 Vaccine Alone or With Adjuvant in Healthy Adults
- ^ clinicaltrials.gov H5 Adult - Chiron Study of Bird Flu Vaccine
- ^ clinicaltrials.gov Study of a Pandemic Influenza Vaccine
- ^ clinicaltrials.gov H5 Aventis Children 2 - 10
| Vaccination/Vaccine (and Immunization, Inoculation. See also List of vaccine topics and Epidemiology) | | Development: Models - Timeline - Toxoid - Trial Administration: ACIP - GAVI - VAERS - Vaccination schedule - VSD Vaccination is the process of administering live, albeit weakened, microbes to patients, with the intent of conferring immunity against a targeted form of a related disease agent. ...
A vaccine is an antigenic preparation used to produce active immunity to a disease, in order to prevent or ameliorate the effects of infection by any natural or wild strain of the organism. ...
Immunization, or immunisation, is the process by which an individual is exposed to an agent that is designed to fortify his or her immune system against that agent. ...
Inoculation, originally Variolation, is a method of purposefully infecting a person with smallpox (Variola) in a controlled manner so as to minimise the severity of the infection and also to induce immunity against further infection. ...
Vaccine topics 2000 Simpsonwood CDC conference AIDS vaccine Andrew Wakefield Edward Jenner Edward Yazbak Generation Rescue Genetics Immunization Immunology Inoculation MMR vaccine Safe Minds Timeline of vaccines Vaccination Vaccine Adverse Event Reporting System Vaccine controversy Vaccines and Fetal Tissue ...
Epidemiologic studies are generally categorized as descriptive, analytic (aiming to examine associations, commonly hypothesized causal relationships), and experimental (a term often equated with clinical or community trials of treatments and other interventions). ...
It is possible to model mathematically the progress of most infectious diseases to discover the likely outcome of an epidemic or to help manage them by vaccination. ...
Timeline of vaccines This is a timeline of the development of prophylactic vaccines. ...
A toxoid is a bacterial toxin whose toxicity as been weakened or supressed while other properties, typically immunogenicity, are maintained. ...
I am an elf. ...
The Advisory Committee on Immunization Practices (ACIP) consists of fifteen advisors to the Centers for Disease Control (CDC), selected by the Secretary of the United States Department of Health and Human Services, to provide advice and guidance on the most effective means to prevent diseases through nation-wide vaccination campaigns. ...
The Global Alliance for Vaccines and Immunization is an alliance between various UN organizations, national governments, private foundations, NGOs and the pharmaceutical industry. ...
The Vaccine Adverse Event Reporting System is a United States program for vaccine safety, co-sponsored by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). ...
Over the past two decades, the recommended vaccination schedule in the United States and elsewhere has grown rapidly and become more complicated as many new vaccines have been developed and marketed. ...
The Vaccine Safety Datalink Project (VSD) was established, in 1990, by the Centers for Disease Control (CDC) for the study of adverse side effects of vaccines. ...
Specific vaccines: Anthrax - BCG - Cancer - DPT - Flu - HIV - HPV - MMR - Pneumonia - Polio - Smallpox Bacillus of Calmette and Guérin (BCG) is a vaccine against tuberculosis that is prepared from a strain of the attenuated (weakened) live bovine tuberculosis bacillus, Mycobacterium bovis that has lost its virulence in humans by specially culturing in artificial medium for years. ...
The term cancer vaccine is often used to describe a process whereby a persons immune system is coaxed into recognizing and destroying malignant cells without harming normal cells. ...
DPT, (sometimes DTP) is a mixture of three vaccines, to immunize against diphtheria, pertussis, and tetanus. ...
Model of Influenza Virus from NIH The flu vaccine is a vaccine to protect against the highly variable influenza virus. ...
An HIV vaccine is a hypothetical vaccine against HIV, the etiological agent of AIDS. As there is no known cure for AIDS, the search for a vaccine has become part of the struggle against the disease. ...
Human papillomavirus vaccine research focuses on the prevention of cervical cancer, particularly in developing countries, where regular cervical examinations are uncommon. ...
The MMR vaccine is a mixture of live but attenuated viruses, administered via injection for immunization against measles, mumps and rubella. ...
This is a vaccine used for Pneumonia, it is usually used for people 65 and older ...
Two polio vaccines are used throughout the world to combat polio. ...
The smallpox vaccine is the only effective preventive treatment for the deadly smallpox disease. ...
Controversy: A-CHAMP - Anti-vaccinationists - NCVIA - Pox party - Safe Minds - Simpsonwood - Thimerosal controversy - Vaccine injury The vaccine controversy encompasses many concerns over the use and lack of use of vaccines - whether vaccination in general or mass vaccination in particular is beneficial to the health of individuals and the population. ...
Advocates for Childrens Health Affected by Mercury Poisoning (A-CHAMP), is a United States political activism group, founded by parents, which advocates on behalf of children who were injured by mercury in thimerosal-containing vaccines, and other toxins. ...
Anti-vaccinationists are those who oppose the practice of vaccination. ...
The National Childhood Vaccine Injury Act (NCVIA) of 1986 (42 U.S.C. §§ 300aa-1 to 300aa-34) was enacted in the United States to reduce the liability of vaccine makers, thereby ensuring a stable market supply, and to provide cost-effective arbitration in cases of possible vaccine injury. ...
A pox party is a normal party for children organised by parents whose kids have the chicken pox. ...
The Coalition for Safe Minds (Sensible Action For Ending Mercury-Induced Neurological Disorders) is a nonprofit organization dedicated to investigating the risks of exposure to mercury from medical products. ...
The 2000 Simpsonwood CDC conference was a meeting convened in June, 2000, by the Centers for Disease Control, held at the isolated Simpsonwood Methodist retreat and conference center in Norcross, Georgia. ...
// Thimerosal controversy In recent years, it has been suggested that thimerosal in childhood vaccines could contribute to or cause neurodevelopmental disorders in children (most notably autism, but also other disorders on the PDD spectrum, such as ADHD). ...
Vaccine injury is a term used in both medicine and law to designate alleged injuries sustained by individuals subsequent to having been vaccinated. ...
| |
Feeds |
Contact